

Collaborating to help more women understand their breast cancer risk



Screening guidelines recommend that women at average risk of breast cancer begin annual screening mammography at age 40 – but women at higher risk of breast cancer can undergo annual mammography starting as early as age 30.*


Our collaboration aims to identify and screen women between the ages of 30-39 who are at an increased risk for breast cancer and should receive earlier evaluation.



Approximately 2 in 5 women between the ages of 30-39 may benefit from either enhanced breast screening, genetic testing, or both**

**Myriad internal data: based on 149,226 patients who completed MyGeneHistory between 12/16/22 and 12/15/23.

How does it work?



By creating a combined pathway for convenient risk screening and assessment, we will identify more patients who can benefit from breast imaging and genetic testing.

Together, we can save more lives.

Reach out to your Myriad and/or Onsite representative to learn more.

Together, creating
a combined
pathway for
comprehensive
screening



Onsite Women's Health

In partnership with forward-thinking providers across the country, Onsite Women's Health offers comprehensive breast imaging services – including 3D screening mammography, automated screening breast ultrasound, diagnostic mammography/breast ultrasound and breast cancer risk assessment. Onsite is committed to saving more women's lives through earlier cancer detection and is materially impacting breast cancer screening compliance and detection rates through offering convenient access to mammography, contracting with breast-focused radiologists and utilizing the most innovative equipment and AI-powered technology available on the market. Since its founding in 2008, Onsite has performed more than two million exams across 26 states.

Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs.

If you are interested in implementing a combined risk assessment program for your patients, reach out to your Myriad and/or Onsite representative to learn more.

*Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. Journal of the American College of Radiology. 2023; 20 (9): 902-914. Accessed February 01, 2024. <https://doi.org/10.1016/j.jarc.2023.04.002>

Myriad Genetics / 322 North 2200 West, Salt Lake City, UT 84116

©2024 Myriad Genetics, Inc. Myriad Genetics, MyRisk, RiskScore, MyGeneHistory, and their associated logos, either trademarks or are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. 0124